Your browser doesn't support javascript.
loading
Can signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) be used as an indicator of endothelial dysfunction in acromegaly patients?
Tufekci, Damla; Nuhoglu, Irfan; Ayan, Sumeyye Sura; Gunay, Yasemin Emur; Coskun, Hulya; Bilginer, Muhammet Cuneyt; Ucuncu, Ozge; Kocak, Mustafa; Yaman, Serap Ozer; Karahan, Suleyman Caner.
Afiliação
  • Tufekci D; Department of Endocrinology and Metabolism, Recep Tayyip Erdogan University Faculty of Medicine, Rize, Turkey. drtufekci@gmail.com.
  • Nuhoglu I; Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Ayan SS; Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Gunay YE; Clinics of Endocrinology and Metabolism, Giresun Training and Research Hospital, Giresun, Turkey.
  • Coskun H; Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Bilginer MC; Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Ucuncu O; Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Kocak M; Department of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Yaman SO; Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
  • Karahan SC; Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
Endocrine ; 82(1): 152-160, 2023 10.
Article em En | MEDLINE | ID: mdl-37450216
PURPOSE: Acromegaly is closely related to increased oxidative stress and endothelial dysfunction (ED). This study aimed to evaluate, for the first time in the literature, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) and endothelial nitric oxide synthase e(NOS) levels in the setting of acromegaly. METHOD: A total of 56 acromegaly patients and a control group composed of 30 healthy volunteers were included in this study. In the postoperative follow-up, patients were grouped as active or in-remission according to their GH and IGF-1 levels in oral glucose stimulation test (OGST). After detailed physical examination of acromegaly patients and the control subjects, 8-hour fasting blood samples were collected to evaluate biochemical parameters including lipid profile, anterior pituitary hormones, and SCUBE-1 and e(NOS) levels. RESULTS: Inactive and active acromegaly was noted in 78.6% and 21.4% of patients, respectively. The median (min-max) SCUBE-1 levels were significantly higher in the inactive acromegaly and active acromegaly groups than in the control group (1.6(0.4-2.4) and 1.8(1.1-2.5) vs. 0.4(0.2-1.0) ng/mL, respectively, p < 0.001 for each). The median (min-max) e(NOS) levels were significantly higher in the inactive acromegaly and active acromegaly groups than in the control group (132.7 (26.8-602.9) and 137.3 (69.7-488.7) vs. 83.9 (16.4-218.7) pg/mL, p = 0.018 and p = 0.048, respectively). We have also detected positive correlations of e(NOS) with leukocyte (r = 0.307, p = 0.021) and neutrophil counts (r = 0.309, p = 0.021). CONCLUSION: Our study revealed for the first time in literature that SCUBE-1 levels, being a novel marker for ED, were significantly higher in acromegaly patients than in control subjects. When supported with clinical studies, SCUBE-1can be used as an early indicator of endothelial damage in acromegaly patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia Limite: Humans Idioma: En Revista: Endocrine Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acromegalia Limite: Humans Idioma: En Revista: Endocrine Ano de publicação: 2023 Tipo de documento: Article